Biotech

All Articles

Regeneron's Opdualag rival presents 57% response fee

.Regeneron is actually back with lasting consequence for its LAG-3 prevention and PD-1 inhibitor com...

AstraZeneca messages data on internal competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early examine the efficiency of its internal antibody-dru...

iTeos- GSK's TIGIT celebrity reveals significant renovation

.After declaring a period 3 launch based upon beneficial midstage results, iTeos and also GSK are ac...

More joint FDA can easily increase rare illness R&ampD: file

.The FDA needs to be even more open and collective to discharge a rise in commendations of rare ailm...

Zenas, MBX, Bicara scalp to Nasdaq in warm day for biotech IPOs

.It's an abnormally hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bicara Thera...

Atea's COVID antiviral falls short to halt hospitalizations in phase 3

.Atea Pharmaceuticals' antiviral has actually fallen short one more COVID-19 test, however the biote...

Neurocrine's offer to save mental illness possibility fails

.Neurocrine Biosciences' mental illness program pivot has neglected. The biotech was actually incapa...

Sanofi spends $110M upfront for late-stage radioligand treatment

.Sanofi has actually created an overdue entry to the radioligand party, paying one hundred million e...

F 2G increases $100M for 2nd try to obtain brand new antifungal to market

.After F2G's 1st attempt to receive a new course of antifungal to market was hindered by the FDA, th...

Moderna targets $1.1 B in R&ampD spending slices, drops 5 plans in the middle of productivity stress

.Moderna has actually vowed to reduce R&ampD spending by $1.1 billion by 2027. The choice to shrink ...